Abbott and AtaCor Medical are joining forces to develop a next-generation implantable cardioverter defibrillator (ICD) system that could change how doctors treat life-threatening heart rhythm disorders, the companies announced on January 12, 2026.
The collaboration pairs AtaCor’s investigational Atalaâ„¢ extravascular ICD lead with Abbott’s extravascular ICD (EV-ICD) system, creating a potentially groundbreaking alternative to traditional ICDs that require leads placed directly inside the heart.
$75 Million Investment Fuels Clinical Trials
AtaCor isn’t coming to the partnership empty-handed. The medical device company recently secured up to $75 million in financing to support its pivotal ALARION EV Study, which will evaluate the safety and effectiveness of the EV-ICD system.
“There is a clear and growing need for extravascular ICD systems that combine a straightforward implant procedure with the ability to deliver the full spectrum of tachyarrhythmia therapies using a small pulse generator,” said AtaCor Medical CEO Rick Sanghera.
What makes this system different? Unlike conventional ICDs that thread leads through veins into the heart, AtaCor’s Atalaâ„¢ lead is implanted via a left parasternal incision with electrodes positioned against the pericardium — the protective sac surrounding the heart. This approach avoids placing hardware inside the heart or blood vessels entirely.
Promising Clinical Progress
The collaboration comes as AtaCor has completed enrollment in its ASCEND EV Pilot Study, with results expected to be presented at the upcoming Asia Pacific Heart Rhythm Society meeting. The company has also launched a broader ASCEND EV study to compare its system’s performance with traditional transvenous ICDs.
“Abbott is committed to advancing transformative therapies in cardiac rhythm management,” said Randel Woodgrift, senior vice president of Abbott’s cardiac rhythm management business. The sentiment was echoed by medical experts in the field.
“The Abbott-AtaCor Investigational system represents an exciting step forward in cardiac care,” said Paul Friedman, M.D., Chair of Cardiovascular Medicine at Mayo Clinic.
For patients with arrhythmias severe enough to warrant an ICD, the stakes couldn’t be higher. Traditional ICDs can save lives but come with risks of infection, lead fracture, and vascular complications that can necessitate risky extraction procedures.
Future-Proofing Cardiac Care
Beyond immediate safety benefits, AtaCor’s approach may offer long-term advantages for patients who might need additional heart procedures later in life.
“The AtaCor team is developing a meaningful solution for patients, while protecting the integrity of the heart for future interventions,” noted Maria Berkman, Chair of the AtaCor Board of Directors.
With the ALARION EV Study set to begin later this year, cardiologists and patients alike will be watching closely. If successful, the Abbott-AtaCor system could represent that rarest of medical innovations — one that’s both less invasive and potentially more effective than the standard of care it aims to replace.
